Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans

Blood (2024) 144 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2024-199102

Published: 2024

Journal Articles

Overcoming High-Risk MDS/AML Post-Allogeneic HSCT: Venetoclax and Azacitidine As Maintenance Therapy

Shintaro Ohga, Takuji Yamauchi, Goichi Yoshimoto, Koji Kato, Koichi Akashi

Blood (2024) 144 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2024-202428

Published: 2024

Journal Articles

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Hiroshi Imanaga, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koshi Akahane, Takeshi Inukai, Koichi Akashi, Takahiro Maeda

Blood (2023) 142 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2023-182620

Published: 2023

Journal Articles

The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Takahiro Maeda, Koichi Akashi

Blood (2023) 142 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2023-188986

Published: 2023

Journal Articles

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Koichi Akashi, Takahiro Maeda

Blood (2022) 140 (Supplement 1): 91–92.

https://doi.org/10.1182/blood-2022-168650

Published: 2022

Journal Articles

A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Tatsuya Terasaki, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koichi Akashi, Takahiro Maeda

Blood (2022) 140 (Supplement 1): 5979.

https://doi.org/10.1182/blood-2022-164647

Published: 2022

Journal Articles

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2022) 139 (5): 748–760.

https://doi.org/10.1182/blood.2021012976

Published: 2022

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2021) 138 (Supplement 1): 2257.

https://doi.org/10.1182/blood-2021-152027

Published: 2021

Journal Articles

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

Fumiaki Jinnouchi, Takuji Yamauchi, Ayano Yurino, Takuya Nunomura, Michitaka Nakano, Chika Iwamoto, Teppei Obara, Kohta Miyawaki, Yoshikane Kikushige, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Katsuto Takenaka

Blood (2020) 135 (19): 1661–1672.

https://doi.org/10.1182/blood.2019002194

Published: 2020

Includes: Supplemental data

Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 912.

https://doi.org/10.1182/blood-2019-129237

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 3784.

https://doi.org/10.1182/blood-2019-129623

Published: 2019

Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 1390.

https://doi.org/10.1182/blood-2019-127047

Published: 2019

Journal Articles

Genome-Wide CRISPR/Cas9 Screen Reveals That the Dcps Scavenger Decapping Enzyme Is Essential for AML Cell Survival

Blood (2017) 130 (Supplement 1): 782.

https://doi.org/10.1182/blood.V130.Suppl_1.782.782

Published: 2017

Journal Articles

Introduction of Macrophage Tolerance By Human SIRPA Knock-in Enhances Peripheral Reconstitution of Human Hematopoiesis in Xenotransplantation Model

Fumiaki Jinnouchi, MD, Katsuto Takenaka, MD PhD, Chika Iwamoto, PhD, Takuji Yamauchi, MD PhD, Ayano Yurino, MD, Takuya Nunomura, MD, Yoshikane Kikushige, MD PhD, Koji Kato, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2016) 128 (22): 29.

https://doi.org/10.1182/blood.V128.22.29.29

Published: 2016

Journal Articles

Introduction of the Kit Mutation into Immunodeficient Mice Enables Xenogeneic Reconstitution of Human Megakaryocyte-Erythroid Hematopoietic System

Yurino Ayano, MD, Takuji Yamauchi, MD PhD, Takuya Nunomura, MD, Yasufumi Uehara, MD, Fumiaki Jinnouchi, MD, Shinya Daitoku, MD, Yuya Kunisaki, MD PhD, Katsuto Takenaka, MD PhD, Koichi Akashi, MD PhD

Blood (2015) 126 (23): 1153.

https://doi.org/10.1182/blood.V126.23.1153.1153

Published: 2015

Journal Articles

Mobilization of Human Immature Hematopoietic Progenitors after Combinatory Use of Bortezomib and Immunomodulatory Drugs

Taro Tochigi, Takatoshi Aoki, MD, Yoshikane Kikushige, MD PhD, Tomohiko Kamimura, MD PhD, Takuji Yamauchi, MD PhD, Koji Kato, MD PhD, Katsuto Takenaka, MDPhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2015) 126 (23): 316.

https://doi.org/10.1182/blood.V126.23.316.316

Published: 2015

Journal Articles

Prior Use of Mogamulizumab to Allogenic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-Versus-Host Disease

Blood (2015) 126 (23): 1940.

https://doi.org/10.1182/blood.V126.23.1940.1940

Published: 2015

Journal Articles

Mutations of Calreticulin in Myeloproliferative Neoplasms Contribute to Disease Progression Not through Inhibition of Phagocytosis, but through Enhanced Proliferation Production of Myeloid Myelo-Erythroid Progenitor Cells

Shinya Daitoku, MD, Katsuto Takenaka, MD PhD, Takuji Yamauchi, MD PhD, Koichi Akashi, MD PhD

Blood (2014) 124 (21): 4594.

https://doi.org/10.1182/blood.V124.21.4594.4594

Published: 2014

Journal Articles

Fibrotic Tissues In Human Primary Myelofibrosis With JAK2 V617F Are Developed Clonally From Malignant Hematopoietic Stem Cells

Takuji Yamauchi, MD, PhD, Takahiro Shima, MD, Katsuto Takenaka, MD, PhD, Toshihiro Miyamoto, MD, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 4106.

https://doi.org/10.1182/blood.V122.21.4106.4106

Published: 2013

NARROW

Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans

Overcoming High-Risk MDS/AML Post-Allogeneic HSCT: Venetoclax and Azacitidine As Maintenance Therapy

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53 -Mutated AML

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53 -Mutated AML

A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Genome-Wide CRISPR/Cas9 Screen Reveals That the Dcps Scavenger Decapping Enzyme Is Essential for AML Cell Survival

Introduction of Macrophage Tolerance By Human SIRPA Knock-in Enhances Peripheral Reconstitution of Human Hematopoiesis in Xenotransplantation Model

Introduction of the Kit Mutation into Immunodeficient Mice Enables Xenogeneic Reconstitution of Human Megakaryocyte-Erythroid Hematopoietic System

Mobilization of Human Immature Hematopoietic Progenitors after Combinatory Use of Bortezomib and Immunomodulatory Drugs

Prior Use of Mogamulizumab to Allogenic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-Versus-Host Disease

Mutations of Calreticulin in Myeloproliferative Neoplasms Contribute to Disease Progression Not through Inhibition of Phagocytosis, but through Enhanced Proliferation Production of Myeloid Myelo-Erythroid Progenitor Cells

Fibrotic Tissues In Human Primary Myelofibrosis With JAK2 V617F Are Developed Clonally From Malignant Hematopoietic Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only